RESUMO
A series of 10 dose confirmation studies was conducted to evaluate the persistent activity of an extended-release injectable (ERI) formulation of eprinomectin against single point challenge infections of gastrointestinal and pulmonary nematodes of cattle. The formulation, selected based on the optimal combination of high nematode efficacy, appropriate plasma profile, and satisfactory tissue residue levels, includes 5% poly(D,L-lactide-co-glycolic)acid (PLGA) and is designed to deliver eprinomectin at a dose of 1.0mg/kg bodyweight. Individual studies, included 16-30 cattle blocked based on pre-treatment bodyweight and randomly allocated to treatment with either ERI vehicle or saline (control), or the selected Eprinomectin ERI formulation. Treatments were administered once at a dose volume of 1 mL/50 kg bodyweight by subcutaneous injection in front of the shoulder. In each study, cattle were challenged with a combination of infective stages of gastrointestinal and/or pulmonary nematodes 100, 120 or 150 days after treatment and were processed for parasite recovery according to standard techniques 25-30 days after challenge. Based on parasite counts, Eprinomectin ERI (1mg eprinomectin/kg bodyweight) provided >90% efficacy (p<0.05) against challenge with Cooperia oncophora and Cooperia surnabada at 100 days after treatment; against challenge with Ostertagia ostertagi, Ostertagia lyrata, Ostertagia leptospicularis, Ostertagia circumcincta, Ostertagia trifurcata, Trichostrongylus axei, and Cooperia punctata at 120 days after treatment; and against challenge with Haemonchus contortus, Bunostomum phlebotomum, Oesophagostomum radiatum and Dictyocaulus viviparus at 150 days after treatment. Results of a study to evaluate eprinomectin plasma levels in cattle treated with the Eprinomectin ERI formulation reveal a characteristic second plasma concentration peak and a profile commensurate with the duration of efficacy. These results confirm that the Eprinomectin ERI formulation can provide high levels of parasite control against a range of nematodes of cattle for up to 5 months following a single treatment.
Assuntos
Antinematódeos/uso terapêutico , Doenças dos Bovinos/tratamento farmacológico , Ivermectina/análogos & derivados , Infecções por Nematoides/veterinária , Animais , Antinematódeos/sangue , Antinematódeos/farmacocinética , Bovinos , Feminino , Injeções , Ivermectina/sangue , Ivermectina/farmacocinética , Ivermectina/uso terapêutico , Masculino , Nematoides/fisiologia , Infecções por Nematoides/tratamento farmacológico , Distribuição Aleatória , Fatores de TempoRESUMO
Seven studies were conducted in commercial grazing operations to confirm anthelmintic efficacy, assess acceptability, and measure the productivity response of cattle to treatment with eprinomectin in an extended-release injectable formulation (ERI) when exposed to nematode infected pastures for 120 days. The studies were conducted under one protocol in the USA in seven locations (Arkansas, Idaho, Louisiana, Minnesota, Missouri, Oregon, and Wisconsin). Each study had 67-68 naturally infected animals for a total of 475 (226 female, 249 male castrate) Angus or beef-cross cattle. The animals weighed 133-335 kg prior to treatment and were approximately 3-12 months of age. The studies were conducted under a randomized block design based on pre-treatment body weights to sequentially form 17 replicates of four animals each within sex in each study. Animals within a replicate were randomly assigned to treatments, one to Eprinomectin ERI vehicle (control) and three to Eprinomectin ERI (5%, w/v eprinomectin). Treatments were administered at 1 mL/50 kg body weight once subcutaneously anterior to the shoulder. All animals in each study grazed one pasture throughout the observation period of 120 days. Cattle were weighed and fecal samples collected pre-treatment and on 28, 56, 84, and 120 days after treatment for fecal egg and lungworm larval counts. Positive fecal samples generally were cultured en masse to determine the nematode genera attributable to the gastrointestinal helminth infection. Bunostomum, Cooperia, Haemonchus, Nematodirus, Oesophagostomum, Ostertagia, and Trichostrongylus, when present, were referred to as strongylids. At all post-treatment sampling intervals, Eprinomectin ERI-treated cattle had significantly (P<0.05) lower strongylid egg counts than vehicle-treated controls, with ≥95% reduction after 120 days of grazing. Over this same period, Eprinomectin ERI-treated cattle gained more weight (43.9 lb/head) than vehicle-treated controls in all studies. This weight gain advantage was significant (P<0.05) in six of the studies with the Eprinomectin ERI-treated cattle gaining an average of 42.8% and the control cattle gaining 33.1% of their initial weight. No adverse reactions were observed in the treated animals.
Assuntos
Antinematódeos/uso terapêutico , Doenças dos Bovinos/tratamento farmacológico , Ivermectina/análogos & derivados , Infecções por Nematoides/veterinária , Animais , Antinematódeos/administração & dosagem , Bovinos , Fezes/parasitologia , Feminino , Injeções , Ivermectina/administração & dosagem , Ivermectina/uso terapêutico , Masculino , Infecções por Nematoides/tratamento farmacológico , Contagem de Ovos de Parasitas/veterinária , Distribuição Aleatória , Aumento de PesoRESUMO
The efficacy of eprinomectin in an extended-release injection (ERI) formulation was evaluated against infections with third-stage larvae or eggs of gastrointestinal and pulmonary nematodes in cattle under 120-day natural challenge conditions in a series of five studies conducted in the USA (three studies) and in Europe (two studies). For each study, 30 nematode-free (four studies) or 30 cattle harboring naturally acquired nematode infections (one study) were included. The cattle were of various breeds or crosses, weighed 107.5-273 kg prior to treatment and aged approximately 4-11 months. For each study, animals were blocked based on pre-treatment bodyweight and then randomly allocated to treatment: ERI vehicle (control) at 1 mL/50 kg bodyweight or Eprinomectin 5% (w/v) ERI at 1 mL/50 kg bodyweight (1.0 mg eprinomectin/kg) for a total of 15 and 15 animals in each group. Treatments were administered once on Day 0 by subcutaneous injection in front of the shoulder. In each study, all animals grazed one naturally contaminated pasture for 120 days. At regular intervals during the studies, fecal samples from all cattle were examined for nematode egg and larval counts. In four studies pairs of tracer cattle were used to monitor pasture infectivity at 28-day intervals before and/or during the grazing period. All calves were weighed before turnout onto pasture and at regular intervals until housing on Day 120. For parasite recovery, all study animals were humanely euthanized 27-30 days after removal from pasture. Cattle treated with Eprinomectin ERI had significantly (p<0.05) fewer strongylid eggs (≤1 egg per gram; egg count reduction≥94%) than the control cattle and zero lungworm larvae at each post-treatment time point. At euthanasia, cattle treated with Eprinomectin ERI had significantly (p<0.05) fewer of the following nematodes than the ERI vehicle-treated (control) cattle with overall reduction of nematode counts by >92%: Dictyocaulus viviparus (adults and fourth-stage larvae (L4), Bunostomum phlebotomum, Cooperia curticei, Cooperia oncophora, Cooperia punctata, Cooperia surnabada, Cooperia spp. inhibited L4, Haemonchus contortus, Haemonchus placei, Haemonchus spp. inhibited L4, Nematodirus helvetianus, Nematodirus spp. inhibited L4, Oesophagostomum radiatum, Oesophagostomum spp. inhibited L4, Ostertagia leptospicularis, Ostertagia lyrata, Ostertagia ostertagi, Ostertagia spp. inhibited L4, Trichostrongylus axei, Trichostrongylus colubriformis, Trichostrongylus spp. inhibited L4, Trichuris discolor, and Trichuris ovis. Over the 120-day grazing period, Eprinomectin ERI-treated cattle gained between 4.8 kg and 31 kg more weight than the controls. This weight gain advantage was significant (p<0.05) in three studies. All animals accepted the treatment well. No adverse reaction to treatment was observed in any animal in any study.
Assuntos
Antinematódeos/uso terapêutico , Doenças dos Bovinos/tratamento farmacológico , Ivermectina/análogos & derivados , Infecções por Nematoides/veterinária , Animais , Antinematódeos/administração & dosagem , Peso Corporal/fisiologia , Bovinos , Doenças dos Bovinos/parasitologia , Fezes/parasitologia , Feminino , Injeções , Ivermectina/administração & dosagem , Ivermectina/uso terapêutico , Masculino , Nematoides/fisiologia , Infecções por Nematoides/tratamento farmacológico , Distribuição AleatóriaRESUMO
Six studies were conducted to evaluate the persistent efficacy of eprinomectin pour-on against experimental challenges with infective nematode larvae in calves. In each study, calves were randomly assigned to one untreated group and up to four test groups, which were treated with eprinomectin at 500 microg/kg body weight at weekly intervals before single bolus challenge. The calves were necropsied approximately 4 weeks after challenge infection for nematode recovery. Eprinomectin pour-on provided > or =90% efficacy against challenge with Haemonchus placei, Trichostrongylus axei and T. colubriformis at 21 days after treatment and against Cooperia oncophora, C. punctata, C. surnabada, Dictyocaulus viviparus, Nematodirus helvetianus, Oesophagostomum radiatum and Ostertagia ostertagi at 28 days after treatment.
Assuntos
Anti-Helmínticos/uso terapêutico , Doenças dos Bovinos/tratamento farmacológico , Ivermectina/uso terapêutico , Nematoides/efeitos dos fármacos , Infecções por Nematoides/veterinária , Administração Tópica , Animais , Bovinos , Doenças dos Bovinos/parasitologia , Ivermectina/análogos & derivados , Nematoides/classificaçãoRESUMO
OBJECTIVE: To determine whether eprinomectin was effective against mange caused by Chorioptes bovis and Sarcoptes bovis in cattle. ANIMALS: 80 cows naturally infested with C bovis and 30 cattle experimentally infested with S bovis. PROCEDURE: 6 trials were performed to determine efficacy against C bovis, and 2 trials were performed to determine efficacy against S bovis. In each trial, a group of untreated animals or of animals treated with vehicle alone was compared with a group of animals treated with a 0.5% formulation of eprinomectin applied topically (500 micrograms/kg). Number of mites in skin scrapings was determined prior to treatment and at weekly intervals for 8 weeks after treatment. Severity of skin lesions was evaluated when skin scrapings were obtained. In 5 trials, animals were weighed before and 56 days after treatment. RESULTS: Mite counts for treated cattle were significantly less than counts for control cattle from day 14 onwards in trials to determine efficacy against C bovis and from day 7 onwards in trials to determine efficacy against S bovis. Mites were not detected in scrapings collected from treated cattle on day 56. Mean weight gain of treated cattle was not significantly different from mean weight gain of control cattle in trials evaluating efficacy against C bovis but was significantly greater in trials evaluating efficacy against S bovis. CONCLUSION AND CLINICAL RELEVANCE: Eprinomectin was highly effective against C bovis and S bovis. Because eprinomectin can be administered to lactating cows, it may be useful for controlling mange in cattle.
Assuntos
Doenças dos Bovinos/tratamento farmacológico , Inseticidas/uso terapêutico , Ivermectina/análogos & derivados , Infestações por Ácaros/veterinária , Ácaros , Escabiose/veterinária , Administração Tópica , Animais , Bovinos , Doenças dos Bovinos/patologia , Doenças dos Bovinos/fisiopatologia , Relação Dose-Resposta a Droga , Feminino , Inseticidas/administração & dosagem , Inseticidas/efeitos adversos , Ivermectina/administração & dosagem , Ivermectina/efeitos adversos , Ivermectina/uso terapêutico , Infestações por Ácaros/tratamento farmacológico , Infestações por Ácaros/patologia , Escabiose/tratamento farmacológico , Escabiose/patologia , Pele/parasitologia , Pele/patologia , Aumento de Peso/fisiologiaRESUMO
The persistence of the effect of ivermectin and abamectin against gastrointestinal nematodes and lungworm in cattle was evaluated in two trials, each involving 28 animals. Groups of seven cattle either remained untreated, or were treated topically with ivermectin at 500 micrograms/kg bodyweight or subcutaneously with either ivermectin or abamectin at 200 micrograms/kg bodyweight. Starting on the day of treatment the cattle were given daily trickle infections with various infective nematode larvae for two weeks (Haemonchus species, Trichostrongylus axei and Cooperia species), three weeks (Ostertagia ostertagi and Oesophagostomum radiatum) and four weeks (Dictyocaulus viviparus). The cattle were killed 49 to 51 days after treatment and their worm burdens measured. An efficacy of > 99 per cent was recorded in all the groups demonstrating that the products controlled Haemonchus species, T axei, C oncophora, C punctata and C surnabada for at least two weeks, O ostertagi and O radiatum for at least three weeks and D viviparus for at least four weeks.
Assuntos
Anti-Helmínticos/uso terapêutico , Antinematódeos/uso terapêutico , Doenças dos Bovinos/tratamento farmacológico , Gastroenteropatias/veterinária , Ivermectina/análogos & derivados , Ivermectina/uso terapêutico , Pneumopatias/veterinária , Infecções por Nematoides/veterinária , Administração Tópica , Animais , Bovinos , Doenças dos Bovinos/parasitologia , Gastroenteropatias/tratamento farmacológico , Gastroenteropatias/parasitologia , Injeções Intravenosas , Pneumopatias/tratamento farmacológico , Pneumopatias/parasitologia , Infecções por Nematoides/tratamento farmacológicoRESUMO
Morphometric and bone density studies were performed on bones from 10 healthy adult dogs and 9 dogs that had exhibited signs of intestinal malabsorption for variable periods of time. The dogs with malabsorption syndrome had a marked decrease in the amount of trabecular bone in lumbar vertebrae (P less than 0.001). Evaluation of undecalcified rib cross sections revealed these dogs had a decrease in trabecular thickness (P less than 0.01) and cortical area (P less than 0.01). There was a decrease in the proportion of the trabecular surface covered with osteoblasts (P less than 0.01) and an increase in resting resorption surface (P less than 0.01) and trabecular specific surface (P less than 0.01). Three of the dogs with malabsorption syndrome and all control dogs were labeled with oxytetracycline prior to sacrifice. The dogs with malabsorption syndrome had a decreased number or complete absence of labeled bone formation sites when compared to controls. No difference was found in bone mineral density in the malabsorption cases as a group, although 1 of the dogs that had an increase in percent osteoid volume and percent osteoid-covered surface had lower ash/ml in trabecular bone samples from lumbar vertebrae. Parathyroid gland weights were available for 6 of the 9 dogs, and these were not significantly different from controls. The findings indicate that decreased bone formation, probably due to the poor nutritional status associated with malabsorption, was an important factor in the development of osteopenia.